Mariana Muñoz-Esquerre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariana Muñoz-Esquerre has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Andújar Ruiz
Respiratory Department, Bellvitge University Hospital - IDIBELL, Barcelona, Spain
1 shared publication- Alicia Padilla-Galo
Hospital Universitario Virgen de la Victoria, Malaga, Spain
1 shared publication - Ana Gómez-Bastero Fernández
Hospital Universitario Virgen Macarena, Sevilla, Spain
1 shared publication Ana Maria Romero-Ortiz
Department of Respiratory Medicine, Bellvitge University Hospital - L’Hospitalet de Llobregat, Barcelona, Spain
1 shared publicationAna Romero Ortíz
Respiratory Department, Bellvitge University Hospital - IDIBELL, Barcelona, Spain
1 shared publicationAna Sogo Sabardía
Service of Pneumology, Consorci Corporacio Sanitaria Parc Tauli De Sabadell, Sabadell, Barcelona, Spain
1 shared publication
Latest Publications
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (12) , 1689-1700
Eosinophilic inflammation in severe asthma: Pathophysiology, clinical identification, and therapeutic implications
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (12) , 1689-1700
Eosinophilic inflammation in severe asthma: Pathophysiology, clinical identification, and therapeutic implications
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...
- Open Access
- 24 April 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 257, 108855
Dupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients
- 24 April 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 257, 108855
Open AccessDupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients
- 6 February 2026
- Published by Sociedad Española de Neumologia y Cirugia Toracica in Revista de Asma
- Vol. 11 (1) , 12-18
Terapia con anticuerpos monoclonales inhalados en asma: ¿tienen futuro?
Los avances en nanotecnología impulsan terapias inhaladas para el asma basadas en nanopartículas y fragmentos de anticuerpos, que ofrecen ventajas frente a los anticuerpos convencionales por su menor tamaño, mejor penetración epitelial y producción más eficiente. Al dirigirse directamente al epitelio de la vía aérea, esta estrategia permite una acción localizada, con altas concentraciones pulmonares y exposición sistémica limitada, mejorando potencialmente el índice terapéutico y reduciendo efectos adversos. Sin embargo, el desarrollo de estos fármacos se enfrenta a importantes barreras tecnológicas, fisicoquímicas y biológicas. Una deposición pulmonar eficaz exige un control preciso del tamaño aerodinámico de las partículas, mientras que los procesos de formulación y aerosolización pueden comprometer la estabilidad estructural de las proteínas, favoreciendo la agregación y aumentando el riesgo de inmunogenicidad. A estas limitaciones se suman mecanismos de aclaramiento pulmonar, como el moco y el aclaramiento mucociliar, la actividad proteolítica, la fagocitosis por macrófagos alveolares y la presencia de biofilm bacteriano, que puede reducir la absorción transepitelial y la biodisponibilidad del fármaco, y hacen crítica la optimización del dispositivo y de la formulación. La evidencia clínica es heterogénea, ya que los primeros ensayos con anti-IgE inhalado no demostraron eficacia y plantearon problemas de seguridad, mientras que los fragmentos inhalados dirigidos frente a IL-13 y TSLP han mostrado actividad farmacodinámica local y buena tolerabilidad en fases tempranas. Los biológicos inhalados (BI) son una aproximación prometedora, cuyo éxito dependerá de demostrar un beneficio clínico claro, garantizar una buena adherencia terapéutica y ajustarse a la complejidad del asma en el contexto de la medicina personalizada.
- 6 February 2026
- Published by Sociedad Española de Neumologia y Cirugia Toracica in Revista de Asma
- Vol. 11 (1) , 12-18
Terapia con anticuerpos monoclonales inhalados en asma: ¿tienen futuro?
Los avances en nanotecnología impulsan terapias inhaladas para el asma basadas en nanopartículas y fragmentos de anticuerpos, que ofrecen ventajas frente a los anticuerpos convencionales por su menor tamaño, mejor penetración epitelial y producción más eficiente. Al dirigirse directamente al epitelio de la vía aérea, esta estrategia permite una acción localizada, con altas concentraciones pulmonares y exposición sistémica limitada, mejorando potencialmente el índice terapéutico y reduciendo efectos adversos. Sin embargo, el desarrollo de estos fármacos se enfrenta a importantes barreras tecnológicas, fisicoquímicas y biológicas. Una deposición pulmonar eficaz exige un control preciso del tamaño aerodinámico de las partículas, mientras que los procesos de formulación y aerosolización pueden comprometer la estabilidad estructural de las proteínas, favoreciendo la agregación y aumentando el riesgo de inmunogenicidad. A estas limitaciones se suman mecanismos de aclaramiento pulmonar, como el moco y el aclaramiento mucociliar, la actividad proteolítica, la fagocitosis por macrófagos alveolares y la presencia de biofilm bacteriano, que puede reducir la absorción transepitelial y la biodisponibilidad del fármaco, y hacen crítica la optimización del dispositivo y de la formulación. La evidencia clínica es heterogénea, ya que los primeros ensayos con anti-IgE inhalado no demostraron eficacia y plantearon problemas de seguridad, mientras que los fragmentos inhalados dirigidos frente a IL-13 y TSLP han mostrado actividad farmacodinámica local y buena tolerabilidad en fases tempranas. Los biológicos inhalados (BI) son una aproximación prometedora, cuyo éxito dependerá de demostrar un beneficio clínico claro, garantizar una buena adherencia terapéutica y ajustarse a la complejidad del asma en el contexto de la medicina personalizada.
- Open Access
- 4 June 2025
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 20 (Vol. 20 (2)
Viability of a new home program of forced spirometry with bronchodilator response measurement in the assessment of patients with asthma
Background: Home spirometry using portable devices offers a potential alternative for asthma management by reducing hospital dependence and improving accessibility. This study aimed to assess the feasibility of a home spirometry program with bronchodilator response (BDR) testing performed without direct medical supervision. Methods: A prospective observational study was conducted with 47 asthma patients from a tertiary hospital. Participants received clear instructions and performed forced spirometry with BDR testing at home using a portable device. The primary outcomes included spirometry quality, variability compared to hospital tests, and patient satisfaction. Results: A total of 78% of participants achieved high-quality spirometry (A or B, according to ATS/ERS criteria), despite greater variability in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) compared to hospital tests. However, the results remained clinically acceptable. Patients reported high satisfaction with the device, highlighting its ease of use and convenience. Conclusions: Home spirometry with BDR testing is a feasible tool for asthma follow-up, maintaining acceptable quality while reducing hospital-based testing. Although improvements are needed to minimize variability and enhance consistency, this program has the potential to optimize asthma management, increase accessibility, and reduce the burden on healthcare facilities.
- 4 June 2025
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 20 (Vol. 20 (2)
Open AccessViability of a new home program of forced spirometry with bronchodilator response measurement in the assessment of patients with asthma
Background: Home spirometry using portable devices offers a potential alternative for asthma management by reducing hospital dependence and improving accessibility. This study aimed to assess the feasibility of a home spirometry program with bronchodilator response (BDR) testing performed without direct medical supervision. Methods: A prospective observational study was conducted with 47 asthma patients from a tertiary hospital. Participants received clear instructions and performed forced spirometry with BDR testing at home using a portable device. The primary outcomes included spirometry quality, variability compared to hospital tests, and patient satisfaction. Results: A total of 78% of participants achieved high-quality spirometry (A or B, according to ATS/ERS criteria), despite greater variability in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) compared to hospital tests. However, the results remained clinically acceptable. Patients reported high satisfaction with the device, highlighting its ease of use and convenience. Conclusions: Home spirometry with BDR testing is a feasible tool for asthma follow-up, maintaining acceptable quality while reducing hospital-based testing. Although improvements are needed to minimize variability and enhance consistency, this program has the potential to optimize asthma management, increase accessibility, and reduce the burden on healthcare facilities.
- Open Access
- 13 February 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1128-1132
Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study
Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities.Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥ 65 years) patients. The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment. 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend towards less frequent comorbid nasal polyps (p = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similar improvements were noted in ACT score (p < 0.0001), comparable exacerbation reductions (p < 0.0001) and lung function parameters (p < 0.04 in elder group and p < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (p = 0.0002). No new safety signals were reported in the elderly population. This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.
- 13 February 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1128-1132
Open AccessEvaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study
Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities.Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥ 65 years) patients. The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment. 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend towards less frequent comorbid nasal polyps (p = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similar improvements were noted in ACT score (p < 0.0001), comparable exacerbation reductions (p < 0.0001) and lung function parameters (p < 0.04 in elder group and p < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (p = 0.0002). No new safety signals were reported in the elderly population. This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.
- 8 May 2021
- Published by Taylor & Francis in Journal of Asthma
- Vol. 59 (6) , 1195-1202
Challenges for asthma units in response to COVID-19: a qualitative group dynamics analysis
To develop a set of recommendations for the management of severe asthma during COVID-19 pandemic. Eleven pneumologists and allergologists who were staff members of officially accredited asthma units in Catalonia (Spain) participated in a cross-section study based on three 2-hour virtual workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 topics, third: establishment of final recommendations by consensus). Impacts and challenges identified were improvement of referral protocols between different levels of care; assessment of the minimum number of function tests to be performed and promote the performance of spirometry in primary care; implementation of videoconferencing, mobile apps, telephone calls, or integral virtual platforms for the follow-up of patients, and definition of the model of care (face-to-face, telematics, mixed) according to the patient’s individual needs; self-administration of biologics for domiciliary treatment; and empowerment of the role of nursing and hospital pharmacy in particular for follow-up and self-administration of biologics. The main recommendations included coordination between primary care and specialized care consultation, optimization of lung function testing, implementation of telemedicine, and the role of nursing and hospital pharmacy. The specific proposals in response to the effect of COVID-19 pandemic focused on four areas of interest (coordination between primary care and specialized care, optimization of lung function testing, implementation of telemedicine, and empowerment of the role of nursing and hospital pharmacy) may be generalized to other health care settings, and help to introduce new ways of caring asthma patients in the COVID-19 context.
- 8 May 2021
- Published by Taylor & Francis in Journal of Asthma
- Vol. 59 (6) , 1195-1202
Challenges for asthma units in response to COVID-19: a qualitative group dynamics analysis
To develop a set of recommendations for the management of severe asthma during COVID-19 pandemic. Eleven pneumologists and allergologists who were staff members of officially accredited asthma units in Catalonia (Spain) participated in a cross-section study based on three 2-hour virtual workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 topics, third: establishment of final recommendations by consensus). Impacts and challenges identified were improvement of referral protocols between different levels of care; assessment of the minimum number of function tests to be performed and promote the performance of spirometry in primary care; implementation of videoconferencing, mobile apps, telephone calls, or integral virtual platforms for the follow-up of patients, and definition of the model of care (face-to-face, telematics, mixed) according to the patient’s individual needs; self-administration of biologics for domiciliary treatment; and empowerment of the role of nursing and hospital pharmacy in particular for follow-up and self-administration of biologics. The main recommendations included coordination between primary care and specialized care consultation, optimization of lung function testing, implementation of telemedicine, and the role of nursing and hospital pharmacy. The specific proposals in response to the effect of COVID-19 pandemic focused on four areas of interest (coordination between primary care and specialized care, optimization of lung function testing, implementation of telemedicine, and empowerment of the role of nursing and hospital pharmacy) may be generalized to other health care settings, and help to introduce new ways of caring asthma patients in the COVID-19 context.